Trevi Therapeutics, Inc. (TRVI) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

9/25

Growth 2 Margin 2 Expansion 3 Platform 0 Financial 2

latest quarter score

Earnings Reports

9
Trevi Therapeutics (TRVI) Q2 2026: $319M Cash Runway Anchors Chronic Cough Leadership Push
August 07, 2026
9
Trevi Therapeutics (TRVI) Q1 2026: $172M Cash Extends Runway to 2030 as Phase 3 Chronic Cough Trials Launch
May 06, 2026
9
Trevi Therapeutics (TRVI) Q4 2025: $188M Cash Runway Extends to 2028, Phase 3 Trials Set for Launch
March 18, 2026
9
Trevi Therapeutics (TRVI) Q3 2025: $115M Raise Extends Runway, Phase 3 Cough Trials Set for 2026
November 14, 2025
9
Trevi Therapeutics (TRVI) Q2 2025: $204M Cash Secured as Phase III Readiness Accelerates
August 08, 2025
7
Trevi Therapeutics (TRVI) Q1 2025: 57% Placebo-Adjusted Cough Reduction Drives Pipeline Inflection
July 05, 2025
8
Trevi Therapeutics (TRVI) Q4 2024: 57% Placebo-Adjusted Reduction in Chronic Cough Validates Haduvio’s Clinical Potential
March 18, 2025

Browse all companies